Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer has an extremely high mortality rate due to its aggressive metastatic nature. Resolving the underlying mechanisms will be crucial for treatment. Here, we found that overexpression of IL-17B receptor (IL-17RB) strongly correlated with postoperative metastasis and inversely correlated with progression-free survival in pancreatic cancer patients. Consistently, results from ex vivo experiments further validated that IL-17RB and its ligand, IL-17B, plays an essential role in pancreatic cancer metastasis and malignancy. Signals from IL-17B–IL-17RB activated CCL20/CXCL1/IL-8/TFF1 chemokine expressions via the ERK1/2 pathway to promote cancer cell invasion, macrophage and endothelial cell recruitment at primary sites, and cancer cell survival at distant organs. Treatment with a newly derived monoclonal antibody against IL-17RB blocked tumor metastasis and promoted survival in a mouse xenograft model. These findings not only illustrate a key mechanism underlying the highly aggressive characteristics of pancreatic cancer but also provide a practical approach to tackle this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918 · cited 1×
“Besides chemokines, numerous target genes of NF-B, which promote cell cycle activity, angiogenesis, anti-apoptosis, metastasis, and tumor progression, have been identified (Baldwin, 2001; Tak and Firestein, 2001; Yamamoto and Gaynor, 2001; Karin, 2006).”
BackgroundCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“2 L). metastasis, and angiogenesis via autocrine or paracrine loop (Coussens and Werb, 2002; Balkwill, 2004).”
BackgroundEMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · cited 2×
“The poor prognosis of pancreatic cancer has been mainly attributed to its aggressive local invasion and early metastasis (Niedergethmann et al., 2007; Rhim et al., 2012).”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“For example, genetic mutations in oncogene KRAS (Almoguera et al., 1988); tumor suppressor genes TP53, SMAD4, and BRCA2 (Hong et al., 2011); chromatin modification genes EPC1 and ARID2; and DNA damage repair gene ATM (Biankin et al., 2012) have been associated with pancreatic cancer progression.”
BackgroundWhitmarsh, A. J., & Davis, R. J. (1996) · Journal of Molecular Medicine · doi:10.1007/s001090050063 · Cited by 1,543 · cited 9×
“(M) Time-course ChIP of NF-B, AP1, ATF2, or AML1 on the chemokine promoters in CFPAC-1 cells treated with 50 ng/ml rIL17B.”
BackgroundInfluentialT cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2593 · Cited by 1,526 · cited 1×
“IL-17A and IL-17F are proinflammatory cytokines exclusively secreted by activated T cells (Fossiez et al., 1996).”
BackgroundGuerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.012 · Cited by 1,224
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · cited 3×
“Because chemokines secreted from cancer cells frequently mediate recruitment of the myeloid cells to tumors to support cancer cell survival and to facilitate metastasis (Acharyya et al., 2012), we then examined whether CCL20, CXCL1, IL-8, and TFF1 are downstream factors mediating biological function of IL-17B–IL-17RB…”
BackgroundDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“Chronic inflammation is also known to serve as a crucial driving force for pancreatic cancer progression (Farrow and Evers, 2002; Clark et al., 2007; Guerra et al., 2007; Rhim et al., 2012).”
BackgroundMcAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · cited 5×
“The cognate receptors for the IL-17 family, IL-17RA to IL-17RE, have been identified, but the physiological roles of these receptors have yet to be fully characterized (Song and Qian, 2013).”
BackgroundInfluential
Cited by
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
Monin, L., & Gaffen, S. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028522 · Cited by 339
γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Daley, D., Zambirinis, C. P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V. R. K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.046 · Cited by 329
Targeting the interleukin-17 immune axis for cancer immunotherapy
Vitiello, G. A., & Miller, G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190456 · Cited by 151
“…via the IL-17R-Act1-TRAF4-MEKK3-ERK5 circuit in skin cancer, and promotes MMP-dependent cell invasion, supports angiogenesis, inhibits TGF-β–dependent cellular apoptosis, and enhances MEK-, ERK-, JNK-, and STAT3-mediated cell proliferation in breast cancer (Fabre et al., 2018; Wu et al., 2015b).”
BackgroundInfluentialHu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Self-citationA positive feedback loop of IL-17B-IL-17RB activates ERK/β-catenin to promote lung cancer metastasis
Yang, Y.-F., Lee, Y.-C., Lo, S., Chung, Y.-N., Hsieh, Y.-C., Chiu, W.-C., & Yuan, S.-S. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.037 · Cited by 52
“We focused on IL-17RB, the receptor responsible for the effects of IL-17B signaling on cancer progression, since a previous study showed that blocking IL-17RB inhibited the invasion and metastatic ability in cancer cells [40].”
BackgroundLaprevotte, E., Cochaud, S., du Manoir, S., Lapierre, M., Dejou, C., Philippe, M., Giustiniani, J., Frewer, K. A., Sanders, A. J., Jiang, W. G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23008 · Cited by 51
“Following the activation of such chemokines, IL-17B promotes the recruitment of macrophages that, in turn, favors cancer cell survival and invasion as well as the recruitment of endothelial cells with vasculogenic potential, thus stimulating tumor angiogenesis [13].”
BackgroundInfluential
Metadata
- Authors
- Wu, H.-H., Hwang-Verslues, W. W., Lee, W.-H., Huang, C.-K., Wei, P.-C., Chen, C.-L., Shew, J.-Y., Lee, E. Y.-H. P., Jeng, Y.-M., Tien, Y.-W., Ma, C., & Lee, W.-H.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-03-02
- Volume
- 212
- Issue
- 3
- Pages
- 333-349
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2136292231
- Cited by
- 157
- References
- 13
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.